MCID: PYD001
MIFTS: 53

Pyoderma Gangrenosum

Categories: Bone diseases, Rare diseases, Skin diseases

Aliases & Classifications for Pyoderma Gangrenosum

MalaCards integrated aliases for Pyoderma Gangrenosum:

Name: Pyoderma Gangrenosum 12 75 53 59 55 44 15 17 72 33

Characteristics:

Orphanet epidemiological data:

59
pyoderma gangrenosum
Prevalence: 1-9/100000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:8553
ICD9CM 35 686.01
MeSH 44 D017511
SNOMED-CT 68 74578003
ICD10 33 L88
MESH via Orphanet 45 D017511
ICD10 via Orphanet 34 L88
UMLS via Orphanet 73 C0085652
Orphanet 59 ORPHA48104
UMLS 72 C0085652

Summaries for Pyoderma Gangrenosum

NIH Rare Diseases : 53 Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. Lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis, Crohn's disease, polyarthritis (an inflammation of several joints together), gammopathy, vasculitis, leukemia, and other conditions. Each year in the United States, pyoderma gangrenosum occurs in about 1 person per 100,000 people. Pyoderma gangrenosum belongs to a group of autoinflammatory skin diseases called neutrophilic dermatoses. Neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections. Ulcerations associated with pyoderma gangrenosum may occur after trauma or injury to the skin, a process called pathergy. Treatment involves wound care and the use of anti-inflammatory agents, including antibiotics, corticosteroids, immunosuppressants, and biologics.

MalaCards based summary : Pyoderma Gangrenosum is related to ileocolitis and ulcerative colitis. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Minocycline and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and breast, and related phenotypes are fever and arthralgia

Wikipedia : 75 Pyoderma gangrenosum is a rare, inflammatory skin disease where painful pustules or nodules become... more...

Related Diseases for Pyoderma Gangrenosum

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 564)
# Related Disease Score Top Affiliating Genes
1 ileocolitis 33.4 TNF NOD2
2 ulcerative colitis 31.7 TNF NOD2 CXCL8
3 inflammatory bowel disease 31.7 TNF NOD2 CXCL8
4 colitis 31.7 TNF NOD2 CXCL8
5 hidradenitis 31.4 TNF NOD2
6 hidradenitis suppurativa 31.2 TNF NOD2
7 scleritis 31.1 TNF ITGB2
8 crohn's colitis 31.1 TNF NOD2 CXCL8
9 granulomatous dermatitis 31.1 TNF NOD2
10 erysipelas 31.1 TNF MEFV
11 vasculitis 30.9 TNF MEFV IFNA2 APOH
12 sapho syndrome 30.9 NOD2 CXCL8
13 intestinal disease 30.8 TNF NOD2 CXCL8
14 pouchitis 30.8 NOD2 CXCL8
15 arthritis 30.6 TNF PSTPIP1 NOD2 CXCL8
16 bacterial infectious disease 30.5 TNF NOD2 CXCL8
17 inflammatory bowel disease 3 30.5 TNF NOD2
18 spondylarthropathy 30.5 TNF NOD2
19 stomatitis 30.3 TNF MEFV IFNA2
20 pharyngitis 30.2 MEFV CXCL8
21 rheumatoid arthritis 30.1 TNF ITGB2 IL1R1 CXCL8
22 proteasome-associated autoinflammatory syndrome 1 30.1 TNF IL1R1 CXCL8
23 peritonitis 30.1 TNF MEFV CXCL8
24 polyarteritis nodosa 30.1 MEFV IFNA2 APOH
25 uveitis 30.0 TNF NOD2 IL1R1 IFNA2
26 pyoderma 30.0 TNF PSTPIP1 NOD2 MEFV ITGB2 IL1R1
27 gastrointestinal system disease 30.0 TNF NOD2 CXCL8
28 bone inflammation disease 29.8 TNF NLRP3 CXCL8
29 endocarditis 29.8 TNF CXCL8 APOH
30 mooren's ulcer 29.7 NLRP3 ITGB2
31 aphthous stomatitis 29.6 TNF NLRP3 MEFV
32 aseptic meningitis 29.0 TNF NLRP3 IL1R1 CXCL8
33 familial mediterranean fever 28.2 TNF PSTPIP1 NOD2 NLRP3 MVK MEFV
34 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 13.1
35 bullous pyoderma gangrenosum 12.7
36 classic pyoderma gangrenosum 12.7
37 vegetative pyoderma gangrenosum 12.7
38 pyoderma gangrenosum-acne-suppurative hidradenitis syndrome 12.7
39 pustular pyoderma gangrenosum 12.6
40 crohn's disease 11.9
41 corticosteroid-sensitive aseptic abscesses 11.5
42 polydactyly, postaxial, type a1 11.5
43 skin disease 11.0
44 neurofibromatosis, type ii 10.9
45 myelodysplastic syndrome 10.8
46 fasciitis 10.7
47 myelofibrosis 10.6
48 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.6
49 necrotizing fasciitis 10.6
50 leukemia 10.6

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:



Diseases related to Pyoderma Gangrenosum

Symptoms & Phenotypes for Pyoderma Gangrenosum

Human phenotypes related to Pyoderma Gangrenosum:

59 32 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
2 arthralgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002829
3 papule 59 32 hallmark (90%) Very frequent (99-80%) HP:0200034
4 skin ulcer 59 32 hallmark (90%) Very frequent (99-80%) HP:0200042
5 myalgia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003326
6 myositis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100614
7 myelodysplasia 59 32 frequent (33%) Frequent (79-30%) HP:0002863
8 inflammation of the large intestine 59 32 frequent (33%) Frequent (79-30%) HP:0002037
9 increased antibody level in blood 59 32 frequent (33%) Frequent (79-30%) HP:0010702
10 rheumatoid arthritis 59 32 frequent (33%) Frequent (79-30%) HP:0001370
11 pustule 59 32 frequent (33%) Frequent (79-30%) HP:0200039
12 atrophic scars 59 32 frequent (33%) Frequent (79-30%) HP:0001075
13 myeloid leukemia 59 32 frequent (33%) Frequent (79-30%) HP:0012324
14 abnormal blistering of the skin 59 32 occasional (7.5%) Occasional (29-5%) HP:0008066
15 skin vesicle 59 32 occasional (7.5%) Occasional (29-5%) HP:0200037

GenomeRNAi Phenotypes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.62 APOH CXCL8 NLRP3 NOD2 TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.62 APOH CXCL8 NLRP3 NOD2 TNF

Drugs & Therapeutics for Pyoderma Gangrenosum

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 21)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
2
Adalimumab Approved Phase 2, Phase 3 331731-18-1 16219006
3 Anti-Bacterial Agents Phase 3
4 Anti-Infective Agents Phase 3
5 Anti-Inflammatory Agents Phase 2, Phase 3
6 Antirheumatic Agents Phase 2, Phase 3
7 Pharmaceutical Solutions Phase 3
8 Ixekizumab Approved, Investigational Phase 2 1143503-69-8
9
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
10 Dermatologic Agents Phase 2
11 Immunosuppressive Agents Phase 2
12 Calcineurin Inhibitors Phase 2
13 Antibodies Phase 1, Phase 2
14 Immunologic Factors Phase 1, Phase 2
15 Antibodies, Monoclonal Phase 1, Phase 2
16 Immunoglobulins Phase 1, Phase 2
17
Infliximab Approved 170277-31-3
18 sodium fluoride Approved 7681-49-4
19 Gastrointestinal Agents
20 Listerine
21 Fluorides

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 Minocycline Treatment in Patients With Idiopathic Pulmonary Fibrosis Being Treated With Standard of Care Therapy- a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
2 A Multi-Center, Randomized, Double-blind, Placebo-controlled Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease Completed NCT00445432 Phase 2, Phase 3
3 A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan Active, not recruiting NCT03311464 Phase 3 adalimumab
4 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02315417 Phase 3 gevokizumab;Placebo;gevokizumab open-label
5 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02326740 Phase 3 gevokizumab;Placebo;gevokizumab open-label
6 A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum Terminated NCT02318914 Phase 3 gevokizumab
7 An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum Completed NCT01882504 Phase 2 gevokizumab
8 A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Completed NCT01965613 Phase 2
9 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Completed NCT03137160 Phase 2
10 Topical Tacrolimus 0.1% Ointment for Treatment of Cutaneous Crohn's Disease Completed NCT01233570 Phase 2 Tacrolimus
11 A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum Completed NCT01302795 Phase 2 Canakinumab
12 Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Recruiting NCT02733094 Phase 1, Phase 2 Secukinumab
13 Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum Recruiting NCT03971643 Phase 2 IFX-1
14 A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum Terminated NCT03072953 Phase 2 APD334
15 A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37) Withdrawn NCT00690846 Phase 2 adalimumab
16 Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Withdrawn NCT00730717 Phase 2 Humira;Humira
17 Cutaneous JAK Expression in Vitiligo and Acne Vulgaris. Unknown status NCT03185312
18 An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum Completed NCT00791557 Infliximab
19 Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease Completed NCT00487396
20 Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Completed NCT00933296
21 Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses Recruiting NCT01952275
22 A Real World, Observational Registry of Chronic Wounds and Ulcers to Assess Quality of Care, Evidence Based Practice and Outcomes Using Linked Electronic Health Record Data Recruiting NCT02280733
23 Genetics and Pathophysiology of Autoinflammatory Disorders. Recruiting NCT00001373
24 Chronic Recurrent Multifocal Osteomyelitis - Search for a Bacterial Cause and Improving Imaging With PET/MRI Recruiting NCT03433287
25 Retrospective Multicenter Observational Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum in Patients Diagnosed With This Pathology Between 2000 and 2015 Not yet recruiting NCT03636737

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Adalimumab
Clofazimine
Etanercept
Gentamicin
SULFAPYRIDINE PWDR
Tacrolimus

Cochrane evidence based reviews: pyoderma gangrenosum

Genetic Tests for Pyoderma Gangrenosum

Anatomical Context for Pyoderma Gangrenosum

MalaCards organs/tissues related to Pyoderma Gangrenosum:

41
Skin, Neutrophil, Breast, Myeloid, T Cells, Bone, Lung

Publications for Pyoderma Gangrenosum

Articles related to Pyoderma Gangrenosum:

(show top 50) (show all 2938)
# Title Authors PMID Year
1
Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome (PAPA syndrome): report of a sporadic case without an identifiable mutation in the CD2BP1 gene. 9 38
19700023 2009
2
Pyrin Modulates the Intracellular Distribution of PSTPIP1. 9 38
19584923 2009
3
PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders. 9 38
19290936 2009
4
The inherited autoinflammatory syndrome: a decade of discovery. 9 38
19768193 2009
5
Autoinflammatory diseases: clinical and genetic advances. 9 38
18347298 2008
6
Autoinflammatory gene mutations in Behçet's disease. 9 38
17213252 2007
7
The systemic autoinflammatory diseases: inborn errors of the innate immune system. 9 38
16724804 2006
8
Autoinflammatory syndromes. 9 38
16466630 2006
9
Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome. 9 38
15916580 2005
10
A common pathway in periodic fever syndromes. 9 38
15324736 2004
11
CD2BP1 and CARD15 mutations are not associated with pyoderma gangrenosum in patients with inflammatory bowel disease. 9 38
15102098 2004
12
Is probiotic use beneficial for skin lesions in patients with inflammatory bowel disease? 38
30244616 2019
13
Pyoderma Gangrenosum of the Finger Associated With Pediatric Ulcerative Colitis. 38
30614954 2019
14
Pyoderma gangrenosum: a too often overlooked facultative paraneoplastic disease. 38
31230113 2019
15
Pyoderma Gangrenosum Associated with Sunitinib: A Case Report. 38
31408027 2019
16
Bilateral pyoderma gangrenosum associated with ulcerative colitis and restorative proctocolectomy. 38
30470567 2019
17
Dermatologic Urgencies and Emergencies: What Every Pathologist Should Know. 38
30785787 2019
18
Extracutaneous involvement of pyoderma gangrenosum. 38
30923901 2019
19
Targeting the gut-skin axis - probiotics as new tools for skin disorder management? 38
31386766 2019
20
[Paraneoplastic skin diseases]. 38
31273399 2019
21
Erosive pustular dermatosis of the scalp: A neutrophilic folliculitis within the spectrum of neutrophilic dermatoses: A clinicopathologic study of 30 cases. 38
30617027 2019
22
End stage scurvy in the developed world: A diagnostic conundrum but not to be mistaken for pyoderma gangrenosum. 38
31154667 2019
23
Pyoderma gangrenosum in a patient with lipoid proteinosis (Urbach-Wiethe disease). 38
30868669 2019
24
A case of pyoderma gangrenosum in hand surgery. 38
31398490 2019
25
Pyoderma Gangrenosum After Common Femoral Artery Endarterectomy and Patch Plasty. 38
31235307 2019
26
Necrotising fasciitis or pyoderma gangrenosum: A fatal dilemma. 38
31418533 2019
27
[Complex treatment of pyoderma gangrenosum after minor trauma and primary surgical intervention with suspected necrotizing fasciitis]. 38
31392345 2019
28
IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation. 38
30738055 2019
29
Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis. 38
31400451 2019
30
Adalimumab plus topical tacrolimus for the treatment of pyoderma gangrenosum: Report of a case. 38
30938050 2019
31
Pyoderma gangrenosum misdiagnosed as necrotising fasciitis or a real association between the two? 38
30897232 2019
32
Canine pyoderma gangrenosum with recurring skin lesions of unknown origin and splenic involvement. 38
31090152 2019
33
Excellent response to bortezomib in a patient with widespread ulcerative pyoderma gangrenosum accompanied by pulmonary involvement and IgA monoclonal gammopathy. 38
31044516 2019
34
Zebras in Foreskin Dermatopathology: A Review. 38
31149956 2019
35
Cutaneous paraneoplastic syndromes. 38
30736994 2019
36
Sweet syndrome with pseudocarcinomatous hyperplasia: A case report and review of the literature. 38
30734344 2019
37
Sequelae of breast pyoderma gangrenosum associated with ulcerative colitis: Impact on breast cancer screening. 38
31077481 2019
38
Pyoderma gangrenosum successfully treated with golimumab: Case report and review of the literature. 38
30980454 2019
39
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 38
30564995 2019
40
A novel topical therapy for resistant and early peristomal pyoderma gangrenosum. 38
31298491 2019
41
Clinical characteristics and treatment outcomes of 36 pyoderma gangrenosum patients - a retrospective, single institution observation. 38
31310348 2019
42
Challenge of diagnosing pyoderma gangrenosum after caesarean section. 38
31352396 2019
43
Pyoderma gangrenosum controlled with rituximab. 38
31312710 2019
44
Pyoderma Gangrenosum After Abdominal Free Tissue Transfer for Breast Reconstruction: Case Series and Management Guidelines. 38
31095530 2019
45
´╗┐The Thin bilateral and bipedicled DIEAP flap for axillary reconstruction in hidradenitis suppurativa. 38
31307106 2019
46
Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: A paradoxical reaction. 38
31115357 2019
47
A case of pyoderma gangrenosum induced by insulin. 38
31353778 2019
48
Incisional pyoderma gangrenosum after caesarean section: Two case reports. 38
31431888 2019
49
Peristomal pyoderma gangrenosum: An exceedingly rare and overdiagnosed entity? 38
30772334 2019
50
Penile pyoderma gangrenosum: Successful treatment with thalidomide. 38
31025475 2019

Variations for Pyoderma Gangrenosum

Expression for Pyoderma Gangrenosum

Search GEO for disease gene expression data for Pyoderma Gangrenosum.

Pathways for Pyoderma Gangrenosum

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 TNF PSTPIP1 NOD2 NLRP3 MEFV ITGB2
2
Show member pathways
13.08 TNF NOD2 ITGB2 IL1R1 IFNA2 CXCL8
3
Show member pathways
12.65 TNF ITGB2 IFNA2 CXCL8
4
Show member pathways
12.1 TNF PSTPIP1 NOD2 NLRP3 MEFV IFNA2
5
Show member pathways
12.02 TNF IL1R1 CXCL8
6
Show member pathways
12.01 TNF NLRP3 IFNA2
7
Show member pathways
11.96 TNF IL1R1 CXCL8
8 11.92 TNF NOD2 ITGB2 IFNA2
9 11.8 TNF IL1R1 CXCL8
10 11.77 TNF ITGB2 CXCL8
11 11.71 TNF IL1R1 CXCL8
12 11.65 TNF ITGB2 CXCL8
13
Show member pathways
11.62 PSTPIP1 NOD2 NLRP3 MEFV
14 11.47 TNF ITGB2 IL1R1 CXCL8
15 11.38 TNF ITGB2 CXCL8
16 11.3 TNF ITGB2 CXCL8
17 11.27 TNF IL1R1 CXCL8
18 11.14 TNF NLRP3 ITGB2 CXCL8
19 11.11 NOD2 NLRP3 MEFV
20 11 NLRP3 IL1R1
21 10.96 TNF CXCL8
22 10.94 TNF NOD2
23 10.84 TNF CXCL8

GO Terms for Pyoderma Gangrenosum

Cellular components related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.02 TNF NOD2 ITGB2 IL1R1 APOH

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.88 PSTPIP1 NOD2 NLRP3 MEFV
2 innate immune response GO:0045087 9.86 PSTPIP1 NOD2 NLRP3 MEFV
3 negative regulation of inflammatory response GO:0050728 9.7 NLRP3 MVK MEFV
4 cellular response to lipopolysaccharide GO:0071222 9.67 TNF NOD2 NLRP3 CXCL8
5 cytokine-mediated signaling pathway GO:0019221 9.65 TNF ITGB2 IL1R1 IFNA2 CXCL8
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.62 TNF NOD2 NLRP3 ITGB2
7 positive regulation of interleukin-1 beta secretion GO:0050718 9.58 NOD2 NLRP3
8 positive regulation of interleukin-8 production GO:0032757 9.57 TNF NOD2
9 microglial cell activation GO:0001774 9.55 TNF ITGB2
10 embryonic digestive tract development GO:0048566 9.54 TNF CXCL8
11 positive regulation of type 2 immune response GO:0002830 9.51 NOD2 NLRP3
12 cellular response to peptidoglycan GO:0071224 9.49 NOD2 NLRP3
13 cellular extravasation GO:0045123 9.48 TNF ITGB2
14 positive regulation of prostaglandin-E synthase activity GO:2000363 9.46 NOD2 ITGB2
15 regulation of inflammatory response GO:0050727 9.46 TNF NOD2 NLRP3 IL1R1
16 detection of biotic stimulus GO:0009595 9.43 NOD2 NLRP3
17 cytokine secretion involved in immune response GO:0002374 9.4 NOD2 NLRP3
18 defense response GO:0006952 9.35 TNF NOD2 NLRP3 IFNA2 CXCL8
19 inflammatory response GO:0006954 9.23 TNF PSTPIP1 NLRP3 MEFV ITGB2 IL1R1

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.7 TNF PSTPIP1 NOD2 NLRP3 MVK MEFV
2 cytokine activity GO:0005125 9.43 TNF IFNA2 CXCL8
3 peptidoglycan binding GO:0042834 9.16 NOD2 NLRP3
4 identical protein binding GO:0042802 9.1 TNF PSTPIP1 NLRP3 MVK MEFV APOH

Sources for Pyoderma Gangrenosum

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....